Technical Analysis for TPTX - Turning Point Therapeutics, Inc.

Grade Last Price % Change Price Change
grade F 36.89 0.03% 0.01
TPTX closed up 0.03 percent on Friday, October 11, 2019, on 70 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent N/A Down Flat
See historical TPTX trend table...

Date Alert Name Type % Chg
MACD Bullish Signal Line Cross Bullish 0.00%
Stochastic Buy Signal Bullish 0.00%
NR7 Range Contraction 0.00%
Oversold Stochastic Weakness 0.00%
Slingshot Bearish Bearish Swing Setup 0.03%
Oversold Stochastic Weakness 0.03%
Wide Bands Range Expansion 3.89%
Oversold Stochastic Weakness 3.89%
Stochastic Reached Oversold Weakness 1.49%
Wide Bands Range Expansion 1.49%

Older signals for TPTX ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company’s lead program, repotrectinib, is a next-generation kinase inhibitor targeting genetic drivers of non-small cell lung cancer and advanced solid tumors. Repotrectinib has shown antitumor activity and durable responses among kinase inhibitor treatment-naïve and pre-treated patients, and is planned to enter a registrational Phase 2 study in the second half of 2019. Turning Point’s kinase inhibitors are designed to bind to their targets with greater precision and affinity than existing therapies, with a novel, compact structure that has demonstrated an ability to potentially overcome treatment resistance common with other kinase inhibitors. The company is driven to develop therapies that mark a turning point for patients in their cancer treatment.
Medicine Cancer Chemical Compounds Treatment Of Cancer Oncology Solid Tumors Non Small Cell Lung Cancer Antineoplastic Drugs Cancer Treatment Cancer Therapies Targeted Therapy Pyrrolidines Signal Transduction Protein Kinase Inhibitors Kinase
Is TPTX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 2 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 58.56
52 Week Low 24.21
Average Volume 259,157
200-Day Moving Average 0.0
50-Day Moving Average 43.2767
20-Day Moving Average 38.7435
10-Day Moving Average 37.057
Average True Range 2.7263
ADX 21.66
+DI 14.6651
-DI 19.2908
Chandelier Exit (Long, 3 ATRs ) 37.7211
Chandelier Exit (Short, 3 ATRs ) 43.6789
Upper Bollinger Band 43.7557
Lower Bollinger Band 33.7313
Percent B (%b) 0.32
BandWidth 25.873759
MACD Line -2.1133
MACD Signal Line -2.1394
MACD Histogram 0.0261
Fundamentals Value
Market Cap 595.92 Million
Num Shares 16.2 Million
EPS -1.33
Price-to-Earnings (P/E) Ratio -27.76
Price-to-Sales 0.85
Price-to-Book 1.17
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 39.55
Resistance 3 (R3) 39.59 38.75 39.10
Resistance 2 (R2) 38.75 38.07 38.73 38.95
Resistance 1 (R1) 37.82 37.66 37.40 37.78 38.81
Pivot Point 36.98 36.98 36.77 36.96 36.98
Support 1 (S1) 36.05 36.30 35.63 36.01 34.97
Support 2 (S2) 35.21 35.89 35.19 34.83
Support 3 (S3) 34.28 35.21 34.68
Support 4 (S4) 34.24